<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00472212</url>
  </required_header>
  <id_info>
    <org_study_id>2001H0401</org_study_id>
    <nct_id>NCT00472212</nct_id>
  </id_info>
  <brief_title>Correction of Farsightedness in Children Study</brief_title>
  <acronym>CHICS</acronym>
  <official_title>Correction of Hyperopia in Children Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Academy of Optometry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Transitions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio Lions Eye Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>College of Optometrists in Vision Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SUNY Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperopia (farsightedness) has been reported to be associated with reduced visual perceptual
      and reading abilities. However, there is controversy regarding whether or not to prescribe
      for low to moderate amounts of hyperopia. The Correction of Hyperopia In Children Study
      (CHICS) is a placebo-controlled, randomized, masked investigation of the effect of spectacle
      correction for moderate amounts of hyperopia on visual function, symptoms, attention, and
      reading skills in children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reading ability</measure>
    <time_frame>6 week primary outcome</time_frame>
    <description>Reading ability as measured by the Kaufman Test of Educational Achievement (K-TEA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Attention</measure>
    <time_frame>6 week primary outcome</time_frame>
    <description>Attention as measured by the Cognitive Assessment System.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>6 week primary outcome</time_frame>
    <description>Improvement in symptoms as measured by a standardized questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual ability</measure>
    <time_frame>6 week primary outcome</time_frame>
    <description>Improvement in accommodative and/or vergence function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Hyperopia</condition>
  <condition>Farsightedness</condition>
  <arm_group>
    <arm_group_label>Spectacles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spectacles with hyperopic lenses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Spectacles with placebo lenses</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glasses for the correction of low to moderate farsightedness</intervention_name>
    <arm_group_label>Spectacles</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glasses with placebo lens</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 6-11 years;

          -  At least +1.00D Hyperopia (farsightedness);

          -  &lt; +4.00D Hyperopia;

          -  &lt; 1.00D Astigmatism;

          -  &lt; 1.00D Anisometropia (difference between the two eyes);

          -  Willing to be randomized;

          -  Best corrected visual acuity of 20/25 or better in each eye;

          -  Willing to wear eyeglasses full-time;

          -  Willing to return for follow-up visits

        Exclusion Criteria:

          -  Previous wear of glasses or contacts for farsightedness/hyperopia;

          -  Eye disease that affects visual function;

          -  Amblyopia (lazy eye);

          -  Strabismus (eye turn);

          -  History of strabismus surgery;

          -  Chronic use of any of the following medications:

               -  Antianxiety agents (Librium, Valium)

               -  Antiarrythmic agents (Cifenline, Cibenzoline)

               -  Anticholinergics (Motion sickness patch - scopolamine)

               -  Bladder spasmolytic (Propiverine)

               -  Chloroquine

               -  Phenothiazines (Compazine, Mellaril, Thorazine)

               -  Tricyclic antidepressants (Elavil, Nortriptyline, Tofranil)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marjean Kulp, OD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Illinois College of Optometry/Illinois Eye Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY College of Optometry/University Optometric Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern College of Optometry</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2007</study_first_submitted>
  <study_first_submitted_qc>May 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2007</study_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Marjean Kulp</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

